465 related articles for article (PubMed ID: 11376869)
1. Transfection of caspase-3 in the caspase-3-deficient Hodgkin's disease cell line, KMH2, results in enhanced sensitivity to CD95-, TRAIL-, and ARA-C-induced apoptosis.
Wrone-Smith T; Izban KF; Ergin M; Cosar EF; Hsi ED; Alkan S
Exp Hematol; 2001 May; 29(5):572-81. PubMed ID: 11376869
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
Ibrahim SM; Ringel J; Schmidt C; Ringel B; Müller P; Koczan D; Thiesen HJ; Löhr M
Pancreas; 2001 Jul; 23(1):72-9. PubMed ID: 11451151
[TBL] [Abstract][Full Text] [Related]
3. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression.
Grotzer MA; Eggert A; Zuzak TJ; Janss AJ; Marwaha S; Wiewrodt BR; Ikegaki N; Brodeur GM; Phillips PC
Oncogene; 2000 Sep; 19(40):4604-10. PubMed ID: 11030149
[TBL] [Abstract][Full Text] [Related]
4. In the erythroleukemic cell line HEL Prostate-apoptosis-response-gene-4 (par-4) fails to down-regulate Bcl-2 and to promote apoptosis.
Boehrer S; Brieger A; Schaaf S; Kukoc-Zivojnov N; Nowak D; Ruthardt M; Hoelzer D; Mitrou PS; Weidmann E; Chow KU
Leuk Lymphoma; 2004 Jul; 45(7):1445-51. PubMed ID: 15359646
[TBL] [Abstract][Full Text] [Related]
5. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells.
Wen J; Ramadevi N; Nguyen D; Perkins C; Worthington E; Bhalla K
Blood; 2000 Dec; 96(12):3900-6. PubMed ID: 11090076
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the interleukin-1beta-converting enzyme/ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease: lack of caspase-3 expression in nodular lymphocyte predominance Hodgkin's disease.
Izban KF; Wrone-Smith T; Hsi ED; Schnitzer B; Quevedo ME; Alkan S
Am J Pathol; 1999 May; 154(5):1439-47. PubMed ID: 10329597
[TBL] [Abstract][Full Text] [Related]
7. Helenalin triggers a CD95 death receptor-independent apoptosis that is not affected by overexpression of Bcl-x(L) or Bcl-2.
Dirsch VM; Stuppner H; Vollmar AM
Cancer Res; 2001 Aug; 61(15):5817-23. PubMed ID: 11479221
[TBL] [Abstract][Full Text] [Related]
8. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention.
Ahmad M; Shi Y
Oncogene; 2000 Jul; 19(30):3363-71. PubMed ID: 10918593
[TBL] [Abstract][Full Text] [Related]
9. Fas antigen (CD95) in pure erythroid cell line AS-E2 is induced by interferon-gamma and tumor necrosis factor-alpha and potentiates apoptotic death.
Tsushima H; Imaizumi Y; Imanishi D; Fuchigami K; Tomonaga M
Exp Hematol; 1999 Mar; 27(3):433-40. PubMed ID: 10089905
[TBL] [Abstract][Full Text] [Related]
10. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.
Odoux C; Albers A; Amoscato AA; Lotze MT; Wong MK
Int J Cancer; 2002 Feb; 97(4):458-65. PubMed ID: 11802207
[TBL] [Abstract][Full Text] [Related]
11. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
12. Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60.
Lamothe B; Aggarwal BB
J Interferon Cytokine Res; 2002 Feb; 22(2):269-79. PubMed ID: 11911810
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells.
Walczak H; Bouchon A; Stahl H; Krammer PH
Cancer Res; 2000 Jun; 60(11):3051-7. PubMed ID: 10850456
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
15. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
16. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
17. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2.
Sinicrope FA; Penington RC
Mol Cancer Ther; 2005 Oct; 4(10):1475-83. PubMed ID: 16227396
[TBL] [Abstract][Full Text] [Related]
18. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis.
Kim JY; Kim YH; Chang I; Kim S; Pak YK; Oh BH; Yagita H; Jung YK; Oh YJ; Lee MS
Oncogene; 2002 May; 21(20):3139-48. PubMed ID: 12082629
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
[TBL] [Abstract][Full Text] [Related]
20. High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells.
Jönsson G; Paulie S; Grandien A
Anticancer Res; 2003; 23(2B):1213-8. PubMed ID: 12820373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
